Phase 2 Trial of <scp>PD</scp> ‐1 Inhibitor Sintilimab in Recurrent/Progressive Meningioma
Sintilimab failed to improve PFS-6 in both grade 1 and grade 2/3 recurrent/progressive meningiomas in this single-arm, single-center, and small-sample trial. When evaluating PD-1 inhibitor treatment for recurrent/progressive meningioma patients, who generally have a longer expected survival and high TMB, the use of the Immunotherapy Response Assessment in Neuro-Oncology (iRANO) criteria may be more appropriate to avoid overlooking potential clinical benefits.
Authors
- Zhen Wu (ORCID: https://orcid.org/0000-0003-1292-5070)
- Chunna Yu
- Feng Chen (ORCID: https://orcid.org/0000-0003-4819-2518)
- Wenting Xie (ORCID: https://orcid.org/0000-0003-4387-7577)
- Yi Lin (ORCID: https://orcid.org/0000-0001-7523-2250)
- Shuo Yin (ORCID: https://orcid.org/0009-0002-7131-2960)
- Xun Kang
- Can Wang (ORCID: https://orcid.org/0000-0002-1136-792X)
- Xiaojie Li (ORCID: https://orcid.org/0000-0002-6666-9888)
- Wenbin Li (ORCID: https://orcid.org/0000-0001-7638-4395)
- Shoubo Yang (ORCID: https://orcid.org/0000-0003-1126-5461)
- Yali Wang (ORCID: https://orcid.org/0000-0003-2258-584X)
Institutions
- Capital Medical University (CN)
- Beijing Tian Tan Hospital (CN)
- Beijing Luhe Hospital Affiliated to Capital Medical University (CN)
- Beijing Tsinghua Chang Gung Hospital (CN)
Publication Details
- Journal
- CNS Neuroscience & Therapeutics
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1111/cns.70659
- Citations
- 1
- Primary Topic
- Meningioma and schwannoma management
- Type
- article
- Field-Weighted Citation Impact
- 1.35